Colorectal Cancer

An overview of data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal) 2021 Annual Meeting, regarding the circulating tumor DNA for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment of patients with colorectal cancer (CRC).

Experts in the management of colorectal cancer (CRC) consider how long patients with early stage disease should receive ctDNA (circulating tumor DNA) monitorization, and provide insight into their personal experience using ctDNA testing.

February 19, 2021 - Multitarget stool DNA test Cologuard could present a potential noninvasive screening method for colorectal cancer, as it has demonstrated high specificity among average-risk patients aged 45 to 49 years.

Nageshwara Arvind Dasari, MD, discusses the rationale to evaluate fruquintinib in the ongoing, phase 3 FRESCO-2 trial in patients with metastatic colorectal cancer.

Zev A. Wainberg, MD, discusses the need to develop chemotherapy-free options in colorectal cancer.

Kristen K. Ciombor, MD, MSCI, discusses responses achieved with preoperative chemoradiation in patients with rectal cancer.

Axel Grothey, MD, discusses the rationale to evaluate patritumab deruxtecan in HER3-positive colorectal cancer.

Kanwal Raghav, MBBS, MD, discusses the utility of chemotherapy-free intervals in colorectal cancer.

Finding a reliable biomarker for minimal residual disease assessment is needed and circulating tumor DNA has shown incredible promise in colon cancer.

A discussion on the evolving role of ctDNA (circulating tumor DNA) testing and monitoring in early-stage colorectal cancer (CRC).

Key opinion leaders discuss their approach for the treatment of patients with stage II/III resectable colorectal cancer (CRC), with special consideration of factors for choosing perioperative therapy and the management of low- vs high-risk patients.

Andrew Coveler, MD, discusses the rationale to evaluate NUC-3373 in metastatic colorectal cancer.

Kristen K. Ciombor, MD, MSCI, discusses ongoing research efforts being made in rectal cancer.

Axel Grothey, MD, highlights recent advancements in CRC treatment, including innovative combinations and emerging agents that are generating excitement in the field.

Experts in CRC discuss questions and management of mCRC.

John Marshall, MD, and Axel Grothey, MD, discuss how molecular testing results guide treatment decisions in patients with mCRC.

February 3, 2021 - The Drive-By Flu-Fecal Immunochemical Test program not only provides safe and socially distanced colorectal cancer screening opportunities during the coronavirus disease 2019 pandemic, but also may help to address screening declines in diverse communities.

February 2, 2021 - ASCO has chosen molecular profiling driving progress in gastointestinal cancers as its Advance of the Year.

Kristen K. Ciombor, MD, MSCI, discusses sequencing treatment options for patients with locally advanced rectal cancer.

Experts in mCRC review data on TAS-102 and discuss how best to sequence therapies in the third or fourth line.

Axel Grothey, MD, and John Marshall, MD, discuss safety results from the ReDOS study of regorafenib in patients with mCRC.

John Marshall, MD, reviews efficacy data from the ReDOS study of regorafenib in patients with mCRC.

Experts in metastatic colorectal cancer review therapeutic options after progression for patients with mCRC.

Experts in metastatic colorectal cancer discuss when and in which patients to use a chemotherapy-free treatment interval.

Axel Grothey, MD, and John Marshall, MD, discuss strategies for optimizing first-line treatment in metastatic colorectal cancer and the role of adjuvant therapy.